THE GENETICS OF SPINAL MUSCULAR ATROPHY
## Contents

**INTRODUCTION**
What is spinal muscular atrophy? 

**INTRODUCTION TO GENETICS**
What is DNA?  
What is a chromosome?  
What is a gene?  
How does the gene make protein?  
What are mutations?  

**SMA INHERITANCE**
What is inheritance?  
How is SMA inherited?  
Autosomal dominant.  
Autosomal recessive.  
X-linked inheritance.  
What is the genetic basis of 5q-SMA?  

**SMN1 MUTATIONS**

**GENETIC TESTING**
What is DNA testing?  
Why do DNA testing?  
What is the difference between Amniocentesis and Chorionic Villus Sampling?  
DNA testing for 5q-SMA.  
SMN diagnostic test.  
Quantitative SMN carrier test.  
How certain are we that individuals with 2 copies of SMN1 are not carriers?  
Do I have to have a DNA test or bank my DNA?  
Why bank DNA?  

**THE SMN2 GENE AS A DISEASE MODIFIER**

**NON-5q FORMS OF SMA**

**FOR MORE INFORMATION**
Mission  
Vision  
Contact Information  
Donations to SMA Research  
Other booklets from FSMA  

**ABOUT FAMILIES OF SMA**  

**Acknowledgements**

**Primary Author:**  
Louise Simard, Ph.D.  
*Professor and Head*  
Department of Biochemistry and Medical Genetics  
University of Manitoba, Canada  

**Reviewers:**  
• Jill Jarecki, Ph.D.  
• Mary Schroth, M.D.  
• Thomas Prior, Ph.D.  
• Kathryn Swoboda, M.D.  
• Laurie Potter  
• Gary Noritz, M.D.  
• Vanessa Battista, MS, CPNP
Introduction

What is Spinal Muscular Atrophy?
Spinal Muscular Atrophy (SMA) is often referred to by a number of terms, including “genetic disease”, “autosomal recessive genetic disorder”, “motor-neuron disease” or a “neuromuscular disease.”

SMA is a genetic disease
Genetic means relating to the genes. Genes are responsible for the vast majority of our traits and our unique characteristics. In SMA, there is a mutation in a gene responsible for a protein that supports normal muscle movement and control of the limbs, abdomen, head and neck, chest and breathing muscles.

SMA is an autosomal recessive genetic disorder
Autosomal recessive refers to how the disease is inherited or passed down from the parents to their child. In SMA, the child who is affected by SMA inherits two copies of a mutated gene, one copy from each parent. While not typically affected by SMA, each parent carries one copy of the mutated SMA gene.

SMA is a motor-neuron disease
Motor-neuron refers to the type of neuron (or nerve) that is affected in SMA. A neuron is a nerve cell that sends and receives messages to and from parts of the body. A motor-neuron is like a wire that sends messages to and from muscles responsible for movement and control in the head, neck, chest, abdomen, legs, and limbs.

In SMA, the motor-neurons in the spinal cord do not have enough of a certain protein, called SMN protein. As a result, these motor-neurons do not function normally and may die, resulting in muscle weakness and atrophy (shrinkage).

SMA is a neuromuscular disease
A neuromuscular disease (NMD) is a disease that affects the peripheral nervous system, which includes the motor-neuron cell body (located within the spinal cord), motor-neuron axons (projections from the cell body to muscles), neuromuscular junctions (the connection between the motor-neuron axons and muscles), or the muscles themselves. The central nervous system includes the brain and the spinal cord. The peripheral nervous system includes everything outside the brain and the spinal cord. The job of the peripheral nervous system is to send information to and from the central nervous system to regulate muscle activity.
What is DNA?

Basic science research looks at the fundamental building blocks of life, including molecules, proteins, cells and genes. Often referred to as “lab” or “bench” research, basic science research is carried out in a laboratory by researchers using microscopes and petri dishes. Other types of research, like translational research (see next section) or clinical research, are based on the findings and clues offered by basic science research.

Basic science research plays a critical role in the discovery and testing of chemical or biological materials that have the potential to become drugs and therapies to treat SMA; and the identification of existing drugs with potential to treat SMA. Testing at this stage is conducted on proteins, cells, and in living animals, but not in humans.

Critical questions in SMA biology, including what is going wrong in the body to cause SMA, are answered by basic science research. It gives researchers many seed ideas or clues that lead to more advanced research.

What is a chromosome?

The complete human genome contains 3 Billion DNA molecules and if we were to stretch out this DNA it would measure 5.7 feet. Hard to imagine that all this material is present in the nucleus of each cell! For this to happen, DNA wraps itself around protein which is then packaged into very compact structures we call chromosomes. Each human cell contains 46 chromosomes or 23 pairs of chromosomes (one chromosome of each pair is inherited from our father and the other is inherited from our mother; see Figure 2.).
What is a gene?
A gene is a specific DNA sequence that contains all of the information to produce a given protein at a specific time and in specific cells. Each gene codes for a particular protein that will have its own responsibilities in cells. One gene might make a protein all the time, in all cells; another gene might make a protein in liver cells for a short period of time. The engine of a gene is called a promoter and it contains most of the information controlling when and where the gene is turned on. The code that is the blueprint for the protein molecule is contained in regions called exons.

How does the gene make protein?
First, the DNA sequence must be copied into a message. This message is the blueprint for protein. The building blocks of this blueprint, called messenger RNA or mRNA, are molecules called ribonucleic acid. The blueprint for protein is included in exons, and exons are separated by DNA sequences called introns. Once the DNA sequence has been copied into RNA, the introns must be removed and the exons brought together by a process called mRNA splicing. Imagine a pair of scissors that cut the RNA at the beginning and end of each exon, removes the intron, followed by a needle and thread that sews the exons together to form a smaller mRNA molecule. The next step in the process is to use the mRNA to make protein. The building blocks of proteins are amino acid molecules. There are 20 different amino acids. It is the particular sequence of amino acids that distinguishes one protein from another. This whole process is outlined in Figure 3.

Figure 3. What genes do: DNA to mRNA to protein. Genes are comprised of DNA that is made into messages called mRNA during cellular processes called transcription and RNA splicing. As shown to the left, this occurs in the area of the cell called the nucleus. mRNA messages contain the blueprint from which specific proteins are produced, for example the SMN protein relevant in SMA. The process of producing protein from the mRNA template is called translation and occurs in the part of the cell called the cytoplasm. This schema was taken from http://fig.cox.miami.edu
What are mutations?

Any mistakes in the DNA sequence will be copied into the RNA transcript and will affect the production of the final protein product. There are many different types of mutations and some examples follow:

• The engine of a gene is called a “promoter”. The promoter drives the production of RNA transcripts, it dictates where, when, and how much RNA is made. Basically, it controls whether a gene is turned on or off. If one has a mutation in the promoter, then too much or too little RNA will be made.

• If a single nucleotide in the DNA is changed, then a different amino acid will be incorporated into the protein. This could alter the folding and the function of the protein itself. These types of single nucleotide changes are called point mutations.

• If small chunks of DNA are completely absent, called a deletion, then the mutant mRNA will produce a protein with an internal chunk missing. Deletions of the SMN1 gene are responsible for SMA.
What is inheritance?
In this context, we are talking about passing on genetic material from one generation to the next. This genetic material is packaged into chromosomes and we inherit half of our chromosomes from our biological father (from sperm) and half from our biological mother (from egg). The fertilized egg that will give rise to all the cells in our body throughout our lifetime contains 22 pairs of autosomes; named chromosomes 1 through 22, and 2 sex chromosomes (see Figure 2). We have two X chromosomes if we are female and one X and one Y chromosome if we are male.

A genetic trait can be dominant or recessive.

**Autosomal dominant** inheritance refers to a trait that is passed from a parent who shows the trait on to a child who will then also show the trait. The trait is expressed even if only one of the inherited genes has a mutation.

**Autosomal recessive** inheritance refers to a trait that is passed on from both parents who carry a mutated gene. Thus, the child must inherit two faulty (mutated) copies of the gene, one from each parent, to show the effects of having faulty genes. Because each parent typically only possesses one faulty copy of the gene, and two faulty copies are required to have the disease, parents do not show any symptoms of having (carrying) one mutated gene.

SMA is an autosomal recessive disease. See Figure 4 (next page).

How is SMA inherited?
5q-SMA is an autosomal recessive genetic disorder. It is caused by mutations in the SMN1 (Survival Motor Neuron) gene that is found on chromosome 5 (hence the name 5q). To develop SMA, an individual must inherit two faulty SMN1 genes, one from each parent.

Because the parents of an affected child typically have only one faulty SMN1 gene each, the parents do not express the trait and do not have SMA. Thus, the product of one normal SMN1 gene is sufficient for normal function and compensates for the one faulty gene. This person is described as a carrier. Each parent of a child with SMA is almost always a carrier. In about 2% of cases they are not. It is estimated that about 1 in 40 people throughout the world are carriers of SMA.
having a child affected by SMA occurs in a pregnancy between two SMA carriers or between a SMA carrier and a person living with SMA. Two carrier parents can produce children who would be affected, carriers, or non-carriers. The diagram above (Figure 4) shows the possible combinations of genes that could occur in any child of two SMA carriers. Each pregnancy has a:

• 25% chance of producing a child who would be affected with SMA,
• 50% chance of producing a child who would be a SMA carrier, and a
• 25% chance of producing a child who would not have SMA and would not be a SMA carrier.

What is X-linked inheritance?
As most of the sex-linked genes are found on the X chromosome, sex-linked inheritance is generally X-linked. Again, a trait can be either dominant or recessive. If the trait is dominant, both females and males will express the trait and a mutation in only one X-linked gene is necessary. If recessive, usually only males will express this trait as they have a single X chromosome.
What is the genetic basis of 5q SMA?

Genetic linkage studies of families with a history of SMA allowed researchers to localize the region containing the gene responsible for SMA to the long arm of chromosome 5 in 1992. Worldwide efforts, and especially the work by Dr. Judith Melki’s research team, resulted in the identification of the SMA gene in 1995; this gene has been named SMN for the “Survival Motor Neuron” gene.

Humans have two nearly identical copies of this gene that have been named SMN1 and SMN2 (see Figure 5a).

The major difference between SMN1 and SMN2 is found in exon 7. There is a single nucleotide difference at the beginning of exon 7 (C for SMN1 and T for SMN2, see Figure 5b) which is important for SMN RNA splicing. Thus the SMN1 mRNA includes exon 7 whereas the SMN2 mRNA generally excludes exon 7 (see Figure 5c).

The presence of exon 7 is critical for the production of fully functional and stable SMN protein. Because the mRNA from the SMN2 gene excludes exon 7, protein made from the SMN2 gene lacks a chunk of the normal protein. Thus, the SMN2 gene alone cannot provide sufficient amounts of fully functional (full-length exon 7-containing) SMN protein that is necessary to maintain survival of motor neurons.

Figure 5. Schematic of a portion of chromosome 5 that contains the two SMN genes. The major difference between the two SMN gene copies is the C (SMN1) to T (SMN2) nucleotide change in exon 7 in their DNA. Because of this difference, SMN2 mostly makes mRNA message that excludes exon 7 and produces a smaller, unstable SMN protein. SMN1 makes mRNA message that includes exon 7 and makes functioning full-length SMN protein. This process is explained below. (a) The SMN1 and SMN2 gene organization on chromosome 5. (b) The SMN genes are turned on by their respective promoters (areas of DNA that turn genes on) in a process call transcription. Transcription results in a preliminary RNA that contains an intermediate blueprint for protein production. (c) The preliminary RNA message is processed in an event called RNA splicing to become a useful blueprint for protein production. RNA splicing removes chunks of RNA called introns from the preliminary message, which are not part of the protein blueprint. The remaining blueprint regions are called exons. Notice exon 7 is missing from the SMN2 mRNA, due to defective RNA splicing. (d) The final mRNA message that results from the splicing process is used as the template for protein production in a process called translation.
SMN1 Mutations

As SMA is an autosomal recessive disorder, individuals with this disease typically have inherited a faulty (mutant) SMN1 gene from each of their parents. The majority of mutations responsible for 5q-SMA are either deletions or gene conversions. See Figure 6.

- A deletion involves partial or complete removal of the SMN1 gene (Figure 6a).
- In a gene conversion, the SMN1 gene is “converted” into an SMN2-like gene because the “C” in exon 7 is changed into a “T” (Figure 6b).

In both cases, deletion and gene conversion, SMA patients are missing SMN1 exon 7, referred to as homozygous absence of SMN1 exon 7. Therefore, SMA patients make insufficient amounts of full-length (exon 7 containing) SMN protein.

The remaining mutations that cause SMA are point mutations that affect only a few nucleotides of the SMN1 gene. These point mutations result in the production of non-functional or unstable SMN protein. (Figure 6c).

Because deletions and gene conversion mutations are very frequent and point mutations are very rare, about 95% of SMA patients are homozygous for deletion/gene conversion mutations: they have deletion/gene conversion mutations on both their chromosome 5’s. Some rare SMA patients (about 5%) are compound heterozygotes: they have a deletion/gene conversion mutation on one of their chromosome 5’s and a point mutation on the other chromosome 5.
Figure 6. This figure illustrates the three types of SMN1 mutations: deletions, gene conversion of SMN1 to SMN2, and single nucleotide point mutations. (a) Xs indicate a deletion. A deletion removes part or all of the SMN1 gene. (b) In the case of gene conversion, the SMN1 gene has been converted to an SMN2-like gene (indicated by the nucleotide change to T). These two types of mutations (deletions and gene conversion events) are the most frequent types found in SMN1. About 95% of 5q-SMA patients have these two types of mutation, and these mutations are easily detected by the current diagnostic test for SMA as they both result in the loss of SMN1 exon 7. (c) Point mutations can also be found in the SMN1 gene, but at a much lower frequency than the other two types of mutations. Shown here are the locations of point mutations that have been found in the SMN1 gene. They are labeled A through T. About 5% of 5q-SMA patients have a deletion or gene conversion mutation on one chromosome and a point mutation on the other chromosome. An individual with this combination of mutations (point mutation with either a deletion or conversion mutation) will not be diagnosed as having SMA using the SMA diagnostic test as only one copy of the SMN1 gene is gone. Rather, this person will look like a carrier using the quantitative carrier test, even though they are symptomatic for SMA.
Genetic Testing

What is DNA testing?
DNA is the genetic material found in each cell of the body. Diagnosis and carrier testing is most often done with a small blood sample which is used to prepare DNA. If you do not have the disease, this DNA can be used to determine if you carry the mutation for the genetic disorder in your family. Prenatal diagnosis is generally carried out using a chorionic villus sample or amniotic fluid cells.

Why do DNA testing?
DNA testing is relevant when a family member has been diagnosed with a genetic disorder and when the gene and the mutations responsible for the genetic disorder have been identified. When this knowledge is available, DNA testing can be done for the following purposes:

- Diagnosis: to determine if you have the specific genetic disorder.
- Carrier testing: to determine if you are a carrier of a genetic disorder.
- Prenatal testing: to determine if your unborn baby has inherited a genetic disorder.

What is the difference between Amniocentesis and Chorionic Villus Sampling?

**Amniocentesis** is the most common type of prenatal test. This test is usually performed after the 14th week of pregnancy. A very fine needle is inserted into the woman's abdomen and amniotic fluid surrounding the fetus is extracted. This fluid contains fetal cells that are used to prepare DNA and then examined for genetic disorders such as SMA. The risk associated with amniocentesis is that 1 in 200 women may miscarry.

**Chorionic Villus Sampling (CVS)** is usually performed as early as the 10th-12th week of pregnancy. A catheter inserted through the vagina or a very thin needle inserted through the abdomen is used to extract samples of the fingerlike structures that form the placenta (the chorionic villi). Once extracted, these cells are used to prepare DNA and then determine if a fetus has a genetic disorder such as SMA. The risk associated with CVS is that 1 in 100 women may miscarry.
DNA testing for 5q SMA.
There are two types of SMN tests:

- One SMN test is used for the DIAGNOSIS of SMA individuals showing muscular atrophy caused by degeneration of motor neurons.
- The second SMN test is used to determine CARRIER STATUS, that is, the possibility of passing on a SMN1 gene mutation to an offspring. This test is offered to individuals with a family history of SMA or to a partner of a known SMA carrier.

SMN diagnostic test.
Because both copies of SMN1 exon 7 are missing in most SMA individuals either through deletion or conversion, a simple DNA test can be done to detect the presence or absence of SMN1. SMN1 will be present when DNA is prepared from individuals with 1 or 2 normal SMN1 genes. SMN1 will be absent when DNA is prepared from individuals with 5q-SMA.

Because about 95% of SMA patients possess DNA changes that can be detected with this test, namely homozygous deletion/gene conversion mutations, the SMN diagnostic test is said to have about 95% sensitivity. This means that the current SMA diagnostic test can detect 95% of SMA patients who have 5q-SMA. The SMN diagnostic test is not informative for non-5q-SMA.

About 1 in 20 (5%) patients with 5q-SMA have rare point mutations that are not detected by the SMN tests described here. Most of these SMA individuals have one SMN1 gene in which SMN1 exon 7 is missing and a second SMN1 gene with a rare point mutation. One must identify SMN1 mutations in both genes in order to confirm that such an individual has 5q-SMA.

Quantitative SMN carrier test.
Carrier Screening is a type of genetic testing. It is an optional laboratory test that uses a small sample of blood. The results will inform the individual if he or she carries or has 1 copy of the mutated or deleted gene and identifies the risk of giving birth to a child with the disease. Carrier screening can be provided to individuals, couples, or population groups considered at risk for certain disorders.

- 1 in 40 people in the general population are SMA carriers for an estimated total of 7.5 million carriers in the U.S.
- 1 in 6,000 babies in the U.S. is born with SMA.

The SMN diagnostic test is not sensitive enough to determine if an individual has one or two copies of SMN1, it can only detect whether SMN1 is present or absent. Therefore, the SMN diagnostic test cannot distinguish between unaffected individuals and SMA carriers.
Genetic Testing continued
A quantitative PCR test is used to determine carrier status. While this test is much more complex and takes more time to complete, it is very sensitive.

- Individuals with 1 copy of SMN1 are 5q-SMA carriers. We can be certain that an individual with just one copy of SMN1 is indeed a 5q-SMA carrier because most chromosome 5’s have only 1 SMN1 gene (about 95%).

How certain are we that individuals with 2 copies of SMN1 are not carriers? In the general population about 2 to 3% of chromosome 5’s have two copies of the SMN1 gene instead of one.

- Even if the carrier test shows that a person has two copies of SMN1, some individuals have 2 copies of SMN1 on just one chromosome and no copies of SMN1 on the second chromosome. This person will be a carrier but this will not be detected by the current carrier tests. This occurs about 2 to 3% of the time.

We also know that brand new mutations are detected in about 2% of families with SMA. A brand new or “de novo” mutation is a mutation that occurs in the egg or sperm, but the same mutation is not present in the parents.

- A parent with a “de novo” mutation in egg or sperm would have 2 copies of SMN1 (non-carrier) in their blood cells, but still be at risk of having a child with SMA by passing a “de novo” mutation in their egg or sperm cells.

*Because of the existence of 2 SMN1 genes on one chromosome, SMN1 point mutations and de novo SMN1 mutations, the sensitivity of the quantitative SMN1 carrier test is not 100%. The quantitative SMN1 carrier test can detect about 90% of carriers in the general population.*

Do I have to have a DNA test?
The decision whether or not to have a DNA test or to bank DNA is a personal one. The family members who would most benefit from DNA testing will depend upon the inheritance pattern of the genetic disorder. A health care professional (physician, genetic counselor, etc.) can help you assess if you would indeed benefit from DNA testing. By seeking this information, you can make a decision that is right for you and/or your family.

Why bank DNA?
If a DNA test for the genetic disorder in your family is not currently available, you can store your DNA (called banking) for when a DNA test becomes available at a future date. This is particularly relevant for non-5q-SMA cases. DNA will be prepared from blood and can be stored for many years.
The SMN2 Gene As A Disease Modifier

The number of copies of the SMN2 gene varies in the population. The number of SMN2 gene copies a person possesses has been shown to modify SMA disease severity: the severity of SMA in people living with the disease broadly correlates with the number of SMN2 gene copies. More copies = less severe. Every person living with SMA has at least one copy of the SMN2 gene, since some amount of SMN protein is required for every type of cell in the human body to survive.

The observed correlation between SMN2 gene copy number and SMA severity has lead to the idea that increasing the amount of SMN produced from the SMN2 gene is an ideal target for drug intervention. Each and every SMA patient possesses at least one SMN2 gene. Therefore, the SMN2 gene can be viewed as a back-up to the lost SMN1 gene in SMA patients. The goal is to increase the amount of SMN protein made by the SMN2 gene, and this can be achieved in several ways:

• The first is by turning up the SMN2 “promoter” to produce more SMN2 mRNA and then SMN protein.

• The second is to correct the defective splicing of the SMN2 mRNA.

• The third is to find drugs that stabilize the protein produced by the SMN2 gene.

A series of compounds such as sodium butyrate, 4-phenylbutrate, valproate, hydroxyurea, aminogangliosides, and aclarubicin have already been reported to increase SMN protein levels from the SMN2 gene in cellular models of SMA. Several of these (valproate, phenyl butyrate and hydroxyurea) have been approved by the FDA for use in other human diseases and are being actively assessed in clinical trials for SMA. Hopefully, the unique genetic situation in SMA, in which a back-up gene (SMN2) is present, will lead us to beneficial drug treatments for this disease.
Non-5q Forms of SMA

A number of additional inherited motor neuron diseases occur that are caused by mutations in genes other than the SMN1 gene. These are referred to as non-5q-SMA diseases, meaning that the genes causing these other forms of SMA are not located in the SMN region of chromosome 5. Similar to 5q-SMA, people with non-5q-SMA also have early muscle weakness but with a number of features that differ from 5q-SMA. These features can include distal rather than proximal weakness, early contractures, diaphragmatic paralysis with early respiratory failure, and cerebellar degeneration. A subset of non-5q-SMA diseases can be diagnosed with DNA diagnostic tests, but for some this is still not possible as the affected genes have not yet been identified. A list of some non-5q-SMA diseases is presented in Table 1.

<table>
<thead>
<tr>
<th>Name</th>
<th>Alternative titles/symbols</th>
<th>Mode of inheritance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spinal and Bulbar Muscular atrophy</td>
<td>SBMA, SMAX1, X-linked 1 Kennedy Disease</td>
<td>X-linked recessive</td>
</tr>
<tr>
<td>Arthrogryposis Multiplex Congenita</td>
<td>AMC, SMAX2, X-linked 2</td>
<td>X-linked recessive</td>
</tr>
<tr>
<td>Spinal Muscular Atrophy, distal, X-linked</td>
<td>SMAX3, DSMAX, X-linked 3</td>
<td>X-linked recessive</td>
</tr>
<tr>
<td>Motor neuronopathy, distal with vocal cord paralysis</td>
<td>DHMNP, type VII, HMN VII, HMN7, Harper-Young myopathy</td>
<td>Autosomal Dominant</td>
</tr>
<tr>
<td>Arthrogryposis Multiplex Congenita, neurogenic type</td>
<td>AMCN</td>
<td>Autosomal Recessive</td>
</tr>
<tr>
<td>SMA, Distal, Type V</td>
<td>DSMAV, dHMMV, HMN</td>
<td>Autosomal Dominant</td>
</tr>
<tr>
<td>SMA with respiratory distress 1</td>
<td>SMARD1, type VI, HMV VI</td>
<td>Autosomal Recessive</td>
</tr>
<tr>
<td>SMA, congenital, scapuloperoneal amyotrophy</td>
<td>SPSMA</td>
<td>Autosomal Dominant</td>
</tr>
<tr>
<td>SMA, proximal, adult</td>
<td>Finkle type</td>
<td>Autosomal Dominant</td>
</tr>
</tbody>
</table>

Table 1. Non-5q-SMAs
For More Information

FSMA website: www.curesma.org
Genetics Section:
www.curesma.org/FSMACommunity/MedicalIssues/Genetics/

The American College of Medical Genetics
(301) 634-7127
www.acmg.net

The American College of Obstetricians and Gynecologists
(800) 762-2264
www.acog.org

National Society of Genetic Counselors
(610) 872-7608
www.nsgc.org

Genetics & IVF Institute
www.givf.com/
About Families of SMA

Families of SMA is a non-profit organization and the largest network of families, clinicians, and research scientists working together to advance SMA research, support families, and educate the public and professional community about SMA. Through numerous chapters in the U.S. and more than 65,000 supporters, FSMA raises millions of dollars every year for SMA research.

Families of Spinal Muscular Atrophy is dedicated to creating a treatment and cure by:

• Funding and advancing a comprehensive research program;
• Supporting SMA families through networking, information and services;
• Improving care for all SMA patients;
• Educating health professionals and the public about SMA;
• Enlisting government support for SMA; and
• Embracing all touched by SMA in a caring community.

Our vision is a world where Spinal Muscular Atrophy is treatable and curable.

Make a Donation to SMA Research Online at: www.curesma.org
or mail a check to Families of SMA
925 Busse Rd., Elk Grove Village, IL 60007
Contacting Families of SMA

**Families of Spinal Muscular Atrophy**
925 Busse Road
Elk Grove Village, IL 60007

Phone: 1-800-886-1762
Fax: 847-367-7623
E-mail: info@fsma.org

Families of SMA on the Web:
[www.curesma.org](http://www.curesma.org)

**Other booklets from Families of SMA:**
- *Caring Choices: For Parents of Infants Newly Diagnosed with SMA*
- *Breathing Basics: Respiratory Care for Children with Spinal Muscular Atrophy*
- *The Family Guide to SMA Research*
- *FSMA Services for Patients and Families*
- *Understanding Spinal Muscular Atrophy*

Date of publication: November 2009

©2009 Families of Spinal Muscular Atrophy

This booklet was produced with generous support from The Angel Baby Foundation.
Fast Facts

1. SMA is an autosomal recessive disease caused by mutations in both copies of the SMN1 gene located on chromosome 5. This is called 5q-SMA.

2. People who have one defective copy of the SMN1 gene are called carriers, and they do not have SMA.

3. More than 98% of the time, both parents of a child with SMA are carriers. In rare cases, mutations in the SMN1 gene can occur during egg or sperm production. In this situation, only one parent will be a carrier of the defective SMN1 gene.

4. When both parents are carriers, with each pregnancy they have a 25% chance of producing a child who would be affected with SMA; a 50% chance of producing a child who would be a SMA carrier; and a 25% chance of producing a child who would not have SMA and would not be a SMA carrier.

5. SMA results from very low amounts of functional SMN protein. Three different classes of mutations can cause SMA: deletions of the SMN1 gene, conversions of the SMN1 gene to a SMN2-like gene, and rare point mutations within the SMN1 gene.

6. Of the three classes of mutations responsible for 5q-SMA, about 95% of patients have SMN1 gene deletions or SMN1 gene conversions. Only about 5% of patients have point mutations in the SMN1 gene.

7. The current DNA diagnostic test for SMA is capable of detecting SMN1 gene deletions and SMN1 gene conversions, but not the point mutations. This means that this test can diagnose about 95% of SMA cases, but not the 5% of patients with point mutations in the SMN1 gene.

8. 95% of SMA cases can be detected prenatally using either amniocentesis or a chorionic villus sample (CVS).

9. Carrier testing can detect 97% of individuals carrying one copy of the SMN1 gene. This test cannot detect the 3% of carriers who have TWO copies of SMN1 on one chromosome and ZERO copies of SMN1 on the second chromosome.

10. Other types of SMA exist, which are not caused by a defect in the SMN1 gene. These diseases are also characterized by childhood muscle weakness and motor neuron loss; however, they have unique characteristics not shared with 5q-SMA. They are caused by mutations in genes other than SMN1, which are located on chromosomes other than chromosome 5.